Corbus Pharmaceuticals
Small molecule therapeutics targeting PI3K delta and CB2 receptors for oncology and inflammatory diseases
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2017
- Rank in peer group#245 of 1449
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 6 granted of 40- PendingCannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofUSPTOApplication 19381891
- PendingCannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofUSPTOApplication 19341744
- PendingCannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofUSPTOApplication 18854216
Show all 40 patent records
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofMay 7, 2026 · Application 19381891Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApr 2, 2026 · Application 19341744Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofAug 7, 2025 · Application 18854216Pending
- ANTI-alpha-V-beta-8 INTEGRIN ANTIBODIES AND USES THEREOFJun 19, 2025 · Application 18980943Pending
- Compositions Of Ajulemic Acid And Uses ThereofOct 26, 2023 · Application 17766638Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsApr 21, 2022 · Application 17336759Pending
- Lipoxin A4 Analogs And Uses ThereofDec 30, 2021 · Application 17287691Pending
- Cannabinoids And Uses ThereofSep 16, 2021 · Application 17058980Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsJul 6, 2021 · US 11,052,066Granted
- Methods And Compositions Relating To Ultrapure 5-(1,1-DIMETHYLHEPTYL)-RESORCINOLJul 1, 2021 · Application 16756944Pending
- Methods For The Treatment Of InfectionDec 31, 2020 · Application 16779251Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsAug 6, 2019 · US 10,369,131Granted
- Methods For The Treatment Of InfectionMay 9, 2019 · Application 16096550Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsDec 18, 2018 · US 10,154,986Granted
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsOct 2, 2018 · US 10,085,964Granted
- Methods Of Treating Fibrotic Diseases Using TETRAHYDROCANNABINOL-11-OIC AcidsMay 3, 2018 · Application 15619089Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsNov 21, 2017 · US 9,820,964Granted
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsOct 31, 2017 · US 9,801,849Granted
- Compositions, Dosages, And Methods Of Using Tetrahydrocannabinol DerivativesJan 26, 2017 · Application 15284106Pending
- Methods Of Treating Fibrotic Diseases Using TETRAHYDROCANNABINOL-11-OIC AcidsDec 22, 2016 · Application 15057017Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsMay 21, 2015 · Application 14546116Pending
- Cannabinoids And Uses ThereofApplication 62910111Pending
- Cannabinoids And Uses ThereofApplication PCTUS2019034965Pending
- Lipoxin A4 Analogs And Uses ThereofApplication 62749335Pending
- Methods And Compositions Relating To Ultrapure 5-(1,1-DIMETHYLHEPTYL)-RESORCINOLApplication PCTUS2018056641Pending
- Cannabinoids And Uses ThereofApplication 62678689Pending
- Methods And Compositions Relating To Ultrapure 5-(1,1-DIMETHYLHEPTYL)-RESORCINOLApplication 62577868Pending
- Methods For The Treatment Of InfectionApplication PCTUS2017030236Pending
- Methods For The Treatment Of InfectionApplication 62470419Pending
- Study of JBT-101 in Mice infected with Pseudomonas Aeruginosa Beads in the LungApplication 62329514Pending
- Ultrapure TETRAHYDROCANNABINOL-11-OIC AcidsApplication PCTUS2014016050Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication PCTUS2025054380Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication PCTUS2025048127Pending
- ANTI-ALPHA-V-BETA-8 Integrin Antibodies And Uses ThereofApplication PCTUS2024060133Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication 63717059Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication 63699952Pending
- ANTI-alpha-V-beta-8 INTEGRIN ANTIBODIES AND USES THEREOFApplication 63609748Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication PCTUS2023017817Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication 63439645Pending
- Cannabinoid Receptor 1 Antagonists/inverse Agonists And Uses ThereofApplication 63328611Pending
Related companies, and why
- Modal TherapeuticsSimilar federal contract value in Biotech · null in contracts
- GATACA, LLCSimilar federal contract value in Biotech · null in contracts
- Heliobiosys, IncSimilar federal contract value in Biotech · null in contracts
- Tenpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Bit BioSimilar federal contract value in Biotech · null in contracts
- Handa Pharmaceuticals, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .